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RESEARCH ARTICLE
Podoplanin regulates the migration of mesenchymal stromal cells
and their interaction with platelets
Lewis S. C. Ward1,*, Lozan Sheriff2, Jennifer L. Marshall1, Julia E. Manning1, Alexander Brill2,3,4,
Gerard B. Nash2 and Helen M. McGettrick1,‡
ABSTRACT
Mesenchymal stromal cells (MSCs) upregulate podoplanin at sites of
infection, chronic inflammation and cancer. Here, we investigated the
functional consequences of podoplanin expression on the migratory
potential of MSCs and their interactions with circulating platelets.
Expression of podoplanin significantly enhanced the migration of
MSCs compared to MSCs lacking podoplanin. Rac-1 inhibition
altered the membrane localisation of podoplanin and in turn
significantly reduced MSC migration. Blocking Rac-1 activity had no
effect on the migration of MSCs lacking podoplanin, indicating that it
was responsible for regulation of migration through podoplanin.When
podoplanin-expressing MSCs were seeded on the basal surface of a
porous filter, they were able to capture platelets perfused over the
uncoated apical surface and induce platelet aggregation. Similar
microthrombi were observed when endothelial cells (ECs) were co-
cultured on the apical surface. Confocal imaging shows podoplanin-
expressing MSCs extending processes into the EC layer, and these
processes could interact with circulating platelets. In both models,
platelet aggregation induced by podoplanin-expressing MSCs was
inhibited by treatment with recombinant soluble C-type lectin-like
receptor 2 (CLEC-2; encoded by the geneClec1b). Thus, podoplanin
may enhance the migratory capacity of tissue-resident MSCs and
enable novel interactions with cells expressing CLEC-2.
KEY WORDS: Mesenchymal stromal cell, Podoplanin, Platelet,
Migration, Endothelial cell
INTRODUCTION
Podoplanin (PDPN or gp38) is a small mucin-type transmembrane
glycoprotein primarily expressed on mesenchymal stromal cells
(MSCs), such as type-1 alveolar cells and fibroblastic reticular cells
(FRCs; reviewed by Ugorski et al., 2016), but not on vascular
endothelial cells (ECs). The physiological role of podoplanin in
tissue-resident MSCs is not well understood, but it is believed to play
a role in embryonic development of the lymphatic system and lungs,
vascular integrity, platelet activation (e.g. Suzuki-Inoue, 2017),
cellular migration and epithelial–mesenchymal transition (Martin-
Villar et al., 2015). Some MSC types show natural variation in
podoplanin expression between individual cell donors (Sheriff et al.,
2018), and in some cases within specific MSC types (e.g. different
fibroblast subpopulations). Moreover, expression of podoplanin can
be modified by MSC responses to inflammatory mediators (Sheriff
et al., 2018; Croft et al., 2016), and is often upregulated in inflamed
tissues (Del Rey et al., 2014; Inoue et al., 2015; Croft et al., 2016;
Hitchcock et al., 2015) and cancer (Schacht et al., 2005), where it
could contribute to further pathology. For instance, in cancer, high
expression correlates with increased invasion and tumour metastasis,
and a poorer prognosis (reviewed by Dang et al., 2014).
Podoplanin is enriched in filopodia-like structures and coupled to
the actin cytoskeleton through ezrin/radixin/moesin (ERM) family
proteins allowing it to regulate cell shape and movement (Martín-
Villar et al., 2006). It can enhance cellular migration of MSCs,
including fibroblast-like cells (Suchanski et al., 2017) and specific
ECs (lymphatic endothelial cells; LECs) (Navarro et al., 2011;
Langan et al., 2018), as well as providing directional cues in
epithelial cells (Martin-Villar et al., 2010). However, studies
examining the involvement of Rho family of GTPases and their
downstream effector proteins have yielded conflicting findings.
Podoplanin signalling through ROCK (herein referring to both
ROCK1 and ROCK2) has been reported to enhance the ability of
cancer-associated fibroblasts (CAFs) to invade collagen matrices
in vitro (Neri et al., 2015) and fibroblast-like cell lines to migrate
across Transwell filters (Suchanski et al., 2017). VEGF-induced
LEC migration (Langan et al., 2018) and FRC contraction of
collagen (Astarita et al., 2015) has also been shown to be dependent
on RhoA. Conversely, blocking either RhoA or ROCK promotes,
rather than inhibits, the invasion of the podoplanin-overexpressing
MCF-7 breast cancer cell line into collagen gels (Wicki et al., 2006;
Petrie et al., 2012). Much of the evidence linking podoplanin with
cellular migration has been gleaned from studies on tumour or
lymphoid stromal cells. As a result, our understanding of its
function in MSCs from healthy tissues is limited.
Podoplanin is the endogenous ligand for C-type lectin-like
receptor 2 (CLEC-2; encoded by the gene Clec1b), which is
expressed by platelets, dendritic cells and circulating CD11b+ Gr-1+
myeloid cells (Lowe et al., 2015). CLEC-2 ligation of podoplanin
has been reported to negatively regulate MSC functions, reducing
FRC contraction (Astarita et al., 2015). By contrast, we recently
reported that MSCs expressing podoplanin induced CLEC-2-
mediated platelet activation, causing platelet depletion when
administered as a systemic cell therapy (Sheriff et al., 2018).
Similar platelet activation and subsequent thrombus formation has
been attributed to interactions between podoplanin-expressing
perivascular cells and circulating platelets in murine models ofReceived 29 June 2018; Accepted 24 January 2019
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deep vein thrombosis (Payne et al., 2017) and Salmonella infection
(Hitchcock et al., 2015), and in patients with podoplanin-positive
brain tumours (Riedl et al., 2017). Indeed, MSC–platelet
interactions and their implications in malignancy have been
extensively reviewed (Yan and Jurasz, 2016). More recently, a
new protective role for the podoplanin–CLEC-2 axis has been
described, where platelets aid recruitment of podoplanin-expressing
macrophages that control bacterial-induced murine sepsis (Rayes
et al., 2017). Others have shown that podoplanin–CLEC-2
interactions regulate the integrity of endothelial–endothelial
and endothelial–stromal cell junctions (Herzog et al., 2013),
which could explain the reduced leakage of platelets from ‘hyper-
permeable’ inflamed vessels in vivo (Boulaftali et al., 2013).
However, the cells expressing podoplanin and CLEC-2 are usually
located in different anatomical compartments (tissue versus blood
respectively) separated by the blood vascular ECs. Moreover, the
mechanisms by which podoplanin-expressing perivascular MSCs
‘breach’ the endothelial layer to interact with circulating platelets in
the absence of vessel damage remains unclear.
Comparing podoplanin-positive and podoplanin-negative
umbilical cord MSCs, we studied the ability of podoplanin to
regulate the motility of subendothelial MSCs and their interaction
with platelets. Expression of podoplanin enhanced MSC migration
in a Rac-1-dependent manner, while ROCK and RhoA–RhoC
had opposing roles in regulating the podoplanin-independent
component of MSC migration. From their subendothelial location,
podoplanin-expressing MSCs are located in close proximity to ECs
in vivo and appear to protrude into a monolayer of resting ECs to
capture flowing platelets through interactions with CLEC-2,
inducing their activation and aggregation in vitro. We propose that
podoplanin expression imparts a pro-migratory phenotype inMSCs,
facilitating their intravasation and interactions with circulating
platelets, and therefore may contribute to vascular integrity and
inflammation-induced thrombosis (thrombo-inflammation).
RESULTS
Expression of podoplanin regulates MSC migration
We have recently reported that umbilical cord MSCs have a natural
variation in their expression of podoplanin (Sheriff et al., 2018).
Initially, we investigated the effect of podoplanin expression on
the migratory capacity of MSCs. Podoplanin expressing MSCs
displayed an enhanced ability to migrate, with significantly greater
numbers transiting through a Transwell filter (Fig. 1A) and
migrating along a collagen gel (Fig. 1B) when compared to MSCs
lacking podoplanin. To ascertain whether this was a direct effect of
podoplanin, we used siRNA to knockdown its expression in MSCs.
Podoplanin siRNA caused a partial, but significant, knockdown of
podoplanin mRNA and protein expression (Fig. 1C,D), which was
sufficient to significantly reduce MSC migration when compared to
that of podoplanin-positive MSCs treated with scrambled siRNA
(Fig. 1E). Migration of podoplanin-negative MSCs was unaffected
by podoplanin siRNA treatment (Fig. S1A). Furthermore, cross-
linking the extracellular domain of podoplanin had no effect on
MSC migration (Fig. S1B). Collectively, these data indicate that the
expression of podoplanin enhances the migratory capacity of MSCs.
Podoplanin mediates MSC migration through Rac-1
Next, we investigated the role of Rho family GTPases and the
ROCK downstream effector protein in mediating podoplanin-
inducedMSCmigration. MSCmigration was significantly impaired
when cells were treated with a non-specific inhibitor against RhoA–
RhoC activation (Fig. 2A). In contrast, inhibition of ROCK
signalling significantly increased MSC migration (Fig. 2B). These
effects were seen for cells with or without podoplanin expression.
The Rac-1 inhibitor NSC23766 caused a dose-dependent reduction
in the migration of podoplanin expressing MSCs, but had no effect
on the migration of cells lacking podoplanin (Fig. 2C). Collectively
these data suggest that all three molecules are involved in MSC
migration: RhoA–RhoC and ROCK act in opposing manners to
regulate podoplanin-independent migration, whereas signalling
through Rac-1 is responsible for the enhanced migratory potential
of podoplanin-expressing MSCs.
Interestingly, podoplanin-expressing MSCs seeded in
microchannels were significantly larger in cell area when compared
to cells lacking podoplanin (Fig. 3A). Inhibition of Rac-1 had no effect
on MSC area (Fig. 3A). We also assessed podoplanin expression by
immunofluorescence microscopy, and found no effect of inhibition of
Rac-1 on the fluorescence intensity of podoplanin (Fig. 3B). On the
other hand, it was evident that the Rac-1 influenced the cellular
location of podoplanin (Fig. 3C). In podoplanin-positive MSCs, 30%
of podoplanin was located in the tips of pseudopods (Fig. 3C,Ci).
Treatment with the Rac-1 inhibitor significantly reduced the proportion
of cells just expressing podoplanin in the tips of pseudopod to 10%
(Fig. 3C), causing podoplanin to be located diffusely in the membrane
and cytoplasm of the cell (Fig. 3Cii). Thus, Rac-1 contributes to the
membrane localisation of podoplanin in MSCs and cell spreading.
Podoplanin-expressing MSCs can interact with flowing
platelets through porous barriers
Increased motility and spreading of podoplanin-expressing MSCs
might provide a means by which they are able to interact with
circulating platelets across an endothelial barrier in vivo. We,
therefore, examined whether podoplanin-expressing MSCs could
protrude across the wall of ‘vascular’ constructs and interact with
flowing platelets through CLEC-2. First, MSCs were seeded on the
basal surface of 3 μm porous filters (where the pores were too small
for the whole MSC cell body to cross; Fig. S2A), and labelled
platelets in whole blood were added to the apical surface of the filter
under static or flow conditions. Individual platelets were observed
scattered across the surface of filters with podoplanin-negative
MSCs (Fig. 4B,E). In contrast, greater levels of platelet adhesion
were observed on the surface of filters with podoplanin-positive
MSCs, and these platelets tended to clump together forming platelet
microthrombi (Fig. 4C,F). Platelet binding and aggregation,
indicative of activation, occurred on the apical surface of 3.0 µm
pore filters in both static (Fig. 4A–C) and flow conditions
(Fig. 4D–F). Under both conditions, platelet binding and
aggregation was significantly greater on apical surface of filters
with podoplanin-expressing MSCs underneath compared with cells
lacking podoplanin (Fig. 4A,D). Thus both podoplanin-positive and
podoplanin-negative MSCs can bind platelets through a filter;
however, the podoplanin-positive cells induce platelet activation,
leading to platelet–platelet interactions and microthrombi formation
(Fig. 4C,F). Of note, neither type of MSC was able to bind platelets
when cultured on 0.4 µm pore filters (Fig. 4A), suggesting this pore
size was too small to allow cellular protrusions.
Pre-treatment of MSCs with recombinant CLEC-2 significantly
reduced platelet coverage (Fig. 4G) and platelet microthrombi
(Fig. 4I) compared to untreated controls (Fig. 4H), indicating
competitive inhibition of platelet activation. To further evaluate the
mechanism meditating the interaction between MSCs and platelets,
whole bloodwas treatedwith a small inhibitor againstαIIbβ3-integrin
(integrillin), which blocks platelet–platelet interactions, but not
platelet–MSC interactions (Sheriff et al., 2018). Integrillin also
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diminished platelet coverage (Fig. 4G), specifically reducing the
number of platelet aggregates (microthrombi) observed, resulting in a
uniform layer of individual platelets adhering to the filter-coated
basally withMSCs (Fig. 4J). Thus, podoplanin-expressingMSCs can
capture platelets from flowing blood, supporting platelet–platelet
aggregation through podoplanin and activation of αIIbβ3-integrin.
We developed a novel in vitro model to represent platelet
interactions at the vessel wall. Here, blood vascular ECs on the
apical surface of the filter were co-cultured with MSCs seeded on
the basal surface Fig. S2B,C. Using this model, significantly more
platelets adhered to and formed microthrombi on co-cultures
incorporating podoplanin-expressing MSCs compared to those
with MSCs lacking podoplanin (Fig. 5A,C,D). To determine
whether platelet binding was a result of interactions with ECs or
with podoplanin-expressing MSCs, we pre-treated co-cultures
with recombinant CLEC-2 prior to perfusion. CLEC-2 protein
significantly reduced platelet coverage (Fig. 5B) and platelet
microthrombi formation (Fig. 5F) compared to untreated co-
cultures (Fig. 5E), to a similar level to that seen for ECs cultured
without MSCs. To account for the possibility that podoplanin might
Fig. 1. Podoplanin expression regulates MSC migration. Podoplanin-negative (PDPN−) and -positive (PDPN+) MSCs were seeded (A) onto an 8 µm
pore filter, or (B) in a spheroid cultured on a collagen matrix. In A, migration was assessed at 48 h by counting the number of cells detached from the upper
and lower chamber. Data are expressed as the number of cells in the lower chamber as a percentage of the total cell count for both chambers. *P<0.05 by unpaired
t-test. In B, migration was assessed at 24 h and 48 h by counting the number of cells migrating along the surface of the collagen matrix and expressing it as
a percentage of the total number of cells seeded. Two-way ANOVA: P<0.05 for time, P<0.01 for podoplanin status; **P<0.01 by Bonferroni post-test.
Representative images of (i) PDPN− and (ii) PDPN+ MSCs migrating away from the spheroid and into the collagen gel. (C–E) Podoplanin-positive MSCs
transfected with Lipofectamine (untreated) containing non-specific siRNA (Scr) or siRNA against podoplanin (PDPN) were seeded onto an 8 µm pore filter.
In C, podoplaninmRNA expression was assessed over 72 h by qPCR and data are expressed as the 2−ΔCT normalised to the percentage of the scrambled control.
Two-way ANOVA: P<0.05 for time, P<0.001 for siRNA duplex; **P<0.01 by Dunnett post-test compared to scrambled control. In D, podoplanin protein
expression was assessed over 72 h by flow cytometry and data expressed as the MFI normalised to the percentage of the scrambled control. Two-way
ANOVA: P<0.01 for siRNA duplex; P>0.05 for time, **P<0.01 by Bonferroni post-test compared to scrambled control. In E, the effect of podoplanin siRNA on
migration was assessed at 48 h by counting the number of cells detached from the upper and lower chamber. Data are expressed as the number of cells in
the lower chamber as a percentage of the total cell count for both chambers. One-way ANOVA: P<0.05; *P<0.05 by Dunnett’s post-test compared to
untreated control. Data are mean±s.e.m. from (A) n=8 PDPN− MSCs and n=7 PDPN+ MSCs, (B) n=2 PDPN− MSCs and n=4 PDPN+ MSCs, and (D,E) n=4
independent experiments using different biological donors for each cell type in each independent experiment. In C, data are mean±s.d. for n=3 independent
experiments each using different biological donors for each cell type, where each data point per experiment was derived from the mean of three technical
replicates.
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be transferred to ECs during co-culture, we assessed podoplanin
expression on ECs following co-culture by flow cytometry and were
unable to detect any expression by flow cytometry [podoplanin
median fluorescence intensity (MFI)=0.58±0.2 mean±s.e.m., n=4
independent experiments with four biological donors per cell type]
or confocal microscopy (Fig. 6D). Thus, a direct interaction between
podoplanin-expressing MSCs and CLEC-2-expressing platelets,
through the endothelial layer must be occurring.
To further assess this, we imaged the cellular organisation of ECs
and MSCs on the filters via confocal microscopy. We observed a
CD31 (also known as PECAM1)-positive monolayer of endothelial
cells in green on the apical surface of the filter (Fig. 6A,D) and a
monolayer of podoplanin and/or CD90 (also known as THY1)
positiveMSCs on the basal surface of the filter, where podoplanin in
red colocalises with CD90 in blue (Fig. 6B). Analysis of z-stacks
through the co-culture filter revealed regions where podoplanin
extended from the basal MSC layer through the middle of the pores
(Fig. 6C), indicating that MSCs are able to extend podoplanin-
containing processes into the filter. Wewere also able to detect faint
podoplanin staining on the same focal plane as CD31 on co-cultures
(Fig. 6A, arrows), but not the EC monolayers (Fig. 6D), indicating
that MSC-derived podoplanin was present on the apical surface on
the filter upon co-culture and therefore capable of interacting with
flowing platelets. Therefore, migratory podoplanin-expressing
MSCs appear to be capable of protruding through the
endothelium in the model vessel wall to trigger podoplanin-
induced activation of captured platelets. Subsequently, we analysed
expression of CD90, podoplanin and CD31 across the umbilical
cord, and around the vasculature (Fig. 6G–L). We observed CD90-
positive MSCs expressing podoplanin in a perivascular location,
neighbouring CD31-positive blood vascular ECs (Fig. 6J,K).
Expression of podoplanin by the MSCs varied, and tended to be
in discrete regions of the cells rather than evenly distributed across
the membrane or cell (Fig. 6H). In some cases, we were able to
detect CD90 and podoplanin in contact with CD31 in the same focal
plane (Fig. 6K), indicating that podoplanin and CD90 double-
positive perivascular MSCs have the ability to extend podoplanin-
containing processes through intact vessel walls in vivo.
DISCUSSION
By using umbilical cord MSCs as a primary cell line, we have
examined the relationship between the expression of podoplanin by
MSCs, their migratory behaviour and ability to interact with
platelets. Podoplanin expression enhanced MSC migration across a
filter and over a collagen gel. Inhibition of Rac-1 altered the
membrane localisation of podoplanin and, in turn, significantly
reduced the migration of podoplanin-expressing MSCs, but had no
effect on the migration of podoplanin-negative MSCs. Thus, Rac-1
mediated the podoplanin-induced MSC migration. We have
demonstrated for the first time that podoplanin-expressing MSCs
in the subendothelial space can protrude through a barrier modelling
the vascular wall (including ECs) to capture flowing platelets and
activate them through CLEC-2 to induce their aggregation. We
propose that podoplanin expression imparts a pro-migratory
phenotype in MSCs, facilitating their intravasation across the
vessel wall and interaction with circulating platelets. Moreover,
the upregulation of podoplanin by perivascular MSCs at sites of
inflammation may contribute to the physiological regulation of
vascular integrity and thrombo-inflammation. On the other hand,
podoplanin presentation could have pathological consequences in
the context of chronic inflammation, cancer and thrombosis.
Podoplanin has previously been reported to enhance the
migration of cancer-associated MSC lines (Suchanski et al., 2017;
Martin-Villar et al., 2010; Neri et al., 2015;Wicki et al., 2006; Petrie
et al., 2012), and, where analysed, MSCs and ECs associated with
with specialised lymphoid tissues (Navarro et al., 2011; Langan
et al., 2018; Astarita et al., 2015). Although we and others agree that
podoplanin confers a pro-migratory phenotype, there is no
consensus on the mechanism(s) by which this is achieved.
We have demonstrated that podoplanin-mediated migration is
dependent on signalling through Rac-1, whereas podoplanin-
independent migration is regulated via RhoA–RhoC and ROCK
in umbilical cord MSCs. Indeed, our images indicate that Rac-1 is
important for regulating the membrane localisation of podoplanin in
MSCs. Previous groups have shown that ectopic expression of
podoplanin triggers the localised recruitment of the ERM protein
ezrin to the plasma membrane region involved in cell–cell contacts,
promoting the internalisation or re-localisation of E-cadherin and
Fig. 2. Podoplanin-dependent MSCmigration is mediated through Rac-1.
Podoplanin-negative (PDPN−) and -positive (PDPN+) MSCs seeded onto an
8 µm pore filter were treated with inhibitors against (A) RhoA–RhoC (CT04),
(B) ROCK (Y27632) or (C) Rac-1 (NSC23766) over a range of concentrations.
Migration was assessed at 48 h by counting the number of cells detached
from the upper and lower chamber. Data are expressed as the number of
cells in the lower chamber as a percentage of the total cell count for both
chambers. In all cases, one-way ANOVA: P<0.01; *P<0.05, **P<0.01 by
Dunnett’s post-test compared to untreated control for each MSC type. Data
are mean±s.e.m. from n=4 independent experiments using different biological
donors for each cell type in each independent experiment.
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increasing epithelial cell motility (Scholl et al., 1999; Martín-Villar
et al., 2005). Rac-1 has also been reported to influence the
endocytosis of E-cadherin, to control adherens junction assembly
and disassembly (Jou and James Nelson, 1998; Kamei et al., 1999;
Akhtar and Hotchin, 2001). Therefore, it is possible that the
podoplanin–ezrin–Rac-1 complex regulates the cellular location of
podoplanin in MSCs to facilitate migration. In contrast to our
findings showing that Rac-1 is important for podoplanin-mediated
migration, studies have indicated that RhoA or ROCK act
downstream of podoplanin to influence MSC migratory patterns
(Suchanski et al., 2017; Neri et al., 2015; Astarita et al., 2015;Wicki
et al., 2006; Petrie et al., 2012). In lymphoid tissue-derived MSCs
(FRCs) podoplanin has been shown to signal via RhoA to support
cellular motility (Langan et al., 2018; Astarita et al., 2015).
Although ROCK has been linked to podoplanin-mediated
migration, conflicting findings have reported increased (Wicki
et al., 2006; Petrie et al., 2012) and decreased (Suchanski et al.,
2017; Neri et al., 2015) levels of migration in cancer-associated
MSC lines treated with ROCK-blocking agents. Thus, it remains
unclear whether ROCK acts to positively or negatively regulate
podoplanin-mediated migration in cancer-associated MSCs. The
existence of cell type-specific and/or disease-induced podoplanin
signal transduction pathways may explain the differences observed
in the mechanism of action of podoplanin shown in this study on
healthy MSCs compared with the literature.
Additionally, the interaction of podoplanin with co-receptors or
binding partners has been proposed to amplify or inhibit its signalling
(reviewed by Astarita et al., 2012). For instance, CD44 reportedly
interacts with podoplanin to promote cellular protrusions and provide
directional cues in cancer-associated epithelial cells (Martin-Villar
et al., 2010). By contrast, podoplanin interactions with CD9 in CHO
cells inhibited pulmonary metastasis (i.e. cell migration) and also
blocked podoplanin-mediated platelet aggregation (Nakazawa et al.,
2008). In both studies, the extracellular domain of podoplanin has
been suggested to be critical for cell migration. Here, we detected
intracellular pools of podoplanin in bothMSCs that were classified as
positive and negative for podoplanin at the cell surface, yet only the
podoplanin-positive MSCs display enhanced migration. Moreover,
modulating surface expression or membrane location of podoplanin
(i.e. the extracellular pool), either with siRNA knockdown or Rac-1
inhibition, significantly impaired the migration of podoplanin-
positive MSCs. Together, these observations would suggest that it
is the membrane-associated pool of podoplanin that facilitates the
enhanced migration of podoplanin-positive MSCs. Further work is
required to elucidate the downstream signalling mediated by
podoplanin in MSCs, along with other cells, and ascertain whether
it is context dependent and/or tissue specific.
It is notable that siRNA treatment could not achieve a better than
∼65% reduction in the surface expression of podoplanin on MSCs.
However, this result is consistent with the published literature
judging by the unquantified western blots presented (Navarro et al.,
2008, 2011) and absolute flow cytometry quantification (Langan
et al., 2018). Indeed, a 50% reduction in podoplanin surface
expression was sufficient to significantly reduce LEC migration in
response to VEGF-A back to baseline levels (Langan et al., 2018).
That ∼65% of surface podoplanin is still detectable after 72 h siRNA
treatment implies the presence of a long-lived portion of constitutive
podoplanin. Langan et al. (2018) have postulated that there are
Fig. 3. Rac-1 inhibition alters the cellular location of podoplanin on MSCs. Podoplanin-negative (PDPN−) and -positive (PDPN+) MSCs treated with or
without the Rac-1 inhibitor NSC23766 (10 µM) for 24 h. Cellular localisation of podoplanin and F-actin was assessed by confocal microscopy. (A) Cell area
was calculated as the total area of F-actin (green) staining divided by the number of nuclei (blue) and expressed as µm2. Two-way ANOVA: P<0.001 for
podoplanin expression, P>0.05 for Rac-1 inhibition; **P<0.01 by Bonferroni post-test compared to PDPN−MSCs. (B) Fluorescence intensity of podoplanin (red)
staining was assessed by using ImageJ and expressed as the integrated density per cell. Two-way ANOVA: P<0.01 for podoplanin expression, P>0.05 for Rac-1
inhibition; *P<0.05 by Bonferroni post-test compared to PDPN− MSCs. (C) The number of cells where podoplanin expression was confined to the tip of
pseudopod was assessed and expressed as the percentage of total number of cells expressing podoplanin. *P<0.05 by paired t-test. Representative images
of (i) untreated or (ii) NSC23766-treated PDPN+ MSCs, where podoplanin is red, F-actin is green and nuclei are blue. Data are mean±s.e.m. from n=4
independent experiments using different biological donors for each cell type in each independent experiment. Scale bars: 10 µm.
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two pools of podoplanin based on the proteins rate of turnover, a
fast and slow pool, which alter the functional effects of podoplanin. In
this scenario, it is possible that the long-lived pool (slow turnover
pool), which is unaffected by siRNA treatment, is not linked to the
migration machinery. Conversely, the fast turnover pool, which is
sensitive to siRNA treatment, may be critical for the regulation of
MSC migration.
Several studies have recently highlighted a protective role
for podoplanin in the maintenance of vascular integrity through
CLEC-2-mediated platelet activation, in the context of blood and
lymphatic vessel development (Schacht et al., 2003; Bianchi et al.,
2017; Fu et al., 2008), lymphocyte recirculation through high
endothelial venules (Herzog et al., 2013; Boulaftali et al., 2013) and
in response to infection (Hitchcock et al., 2015). Indeed, our data
would support this concept. Consistent with our observations here,
these studies report unevenly dispersed clumps of platelet aggregates
on the vessel wall. Until this study, it had been unclear how cells in the
subendothelial space would come into contact with platelets in the
vessel lumen through a continuous endothelial layer. We have strong
evidence that MSCs, but not ECs, present podoplanin to the luminal
surface both in vitro and in vivo. Our data demonstrate that MSCs can
extend podoplanin-expressing processes through pores of a filter
in vitro. In the umbilical cord, perivascular umbilical cord MSCs are
the major source of podoplanin. Interestingly, dots of CD90 and
Fig. 4. Subendothelial MSCs interact with platelets through a filter. Podoplanin-negative (PDPN−) and -positive (PDPN+) MSCs seeded on the basal
surface of (A) 0.4 µm or (A–C) 3.0 µm pore filters for 24 h. (A) MSCs were incubated with platelet-labelled whole blood for 1 h under static conditions.
Two-way ANOVA: P<0.01 for podoplanin status, P<0.001 for pore size; *P<0.05 by Bonferroni post-test compared to PDPN− donors. Representative images
of (B) PDPN− MSCs and (C) PDPN+ MSCs on 3.0 µm pore filters. (D) Platelet-labelled whole blood was perfused over the apical surface of filters coated with
MSCs on the basal surface for 5 or 10 min. Two-way ANOVA: P<0.001 for podoplanin status, P<0.01 for time; *P<0.05, **P<0.01 by Bonferroni post-test
compared to PDPN− donors. Representative images of (E) PDPN− MSCs and (F) PDPN+ MSCs at 10 min. (G) MSCs were left untreated or treated with
recombinant CLEC-2 (rCLEC-2) prior to perfusion of platelet-labelled whole blood over the over the apical surface of filters coated with MSCs on the basal
surface for 5 min. Additionally, platelet-labelled whole blood was treated with the αIIbβ3-integrin small molecular inhibitor integrilin immediately prior to perfusion.
One-way ANOVA: P<0.01; **P<0.01 by Dunnett’s post-test compared to the untreated MSC control. Representative images of platelet interactions with
(H) untreated MSCs, (I) MSCs pre-treated with rCLEC-2 and (J) integrilin-treated whole blood binding to untreated MSCs. In all cases, platelet adhesion and
aggregation were assessed using ImageJ particle analysis and expressed as platelet coverage in µm2. Data are mean±s.e.m. from (A,G) n=4 and (D) n=3
independent experiments using different biological donors for each cell type in each independent experiment; n≥5 fields of view were analysed per treatment
group. Scale bars: 200 µm.
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podoplanin, possibly forMSC protrusions, can be seen in contact with
CD31-positive blood vascular ECs. To the best of our knowledge, the
role for podoplanin on umbilical cord MSCs in the underlying
physiology of the umbilical cord remains unknown. One possibility is
that podoplanin and CLEC-2 interactions have a role in the
maintenance of vascular integrity and vessel development, which
would be crucial for the underlying biology of the umbilical cord, but
further work is required in this tissue. Collectively, these data suggest
MSCs can extend podoplanin-containing processes through intact EC
monolayers and vessel walls, where it is able to interact with CLEC-2
on platelets in blood to induce aggregation. This process is likely to be
redundant in discontinuous, sinusoidal vascular beds of the liver
(Hitchcock et al., 2015) and spleen (Onder et al., 2011), where
podoplanin-expressing perivascular cells (macrophages or MSCs) are
exposed to the circulation allowing direct interaction with platelets.
Notably, neither of these studies specifically reported the protrusion of
podoplanin-expressing cells into the vessel lumens. Such interactions
are likely to be highly dependent on the physical forces exerted on the
individual cells, and their receptors/ligands. For instance, we have
reported that LECs can capture platelets from flow over a range of
shear rates; however, the optimal conditions needed, as used here,
were equivalent to those of the venous network (Navarro-Núñez et al.,
2015). However, the exact impact of CLEC-2 on podoplanin function
in MSCs during inflammation remains to be fully determined.
In addition to the protective roles described, podoplanin is
commonly upregulated in pathogenic tissues [e.g. rheumatoid joint,
various cancers (Payne et al., 2017; Del Rey et al., 2014; Inoue et al.,
2015; Schacht et al., 2005)] where it is believed to play a role in
pathology. Indeed, patients with podoplanin-positive brain tumours
had significantly reduced platelet counts and increased risk of
thromboembolism (Riedl et al., 2017). Moreover, microthrombi
containing podoplanin-positive tumour cells have been reported to
become trapped in pulmonary vessels, enabling tumour metastasis
(Kunita et al., 2007). Studies have also suggested that podoplanin–
CLEC-2-induced platelet activation promotes tumour growth
(Miyata et al., 2017) and facilitates epithelial-to-mesenchymal
transition (Takemoto et al., 2017). In inflammation, podoplanin in
the vessel wall induced thrombus formation in a murine model of
deep vein thrombosis (Payne et al., 2017). The cellular source of
perivascular podoplanin in that model remains to be determined, but
was not thought to come from either hematopoietic or ECs (Payne
et al., 2017). Hence, the role of podoplanin in eliciting either a
protective or pathogenic response at the blood–stroma interface
appears to be dependent on the context of its interaction with other
cell types. By using umbilical cord MSCs as a primary cell line, we
clearly demonstrate that the presence of podoplanin, in the absence
of any disease-induced cell transformations, is sufficient to enhance
cellular migration. Indeed, our evidence indicates that podoplanin is
an intrinsic promoter of migration when expressed, and does not
require external ligation. This is likely to be important in the
perivascular niche to allow rapid MSC mobilisation to sites of
angiogenesis and tissue damage, to facilitate vessel growth and
tissue repair, respectively. Understanding such interactions are key
to developing novel therapeutic targets based on influencing the
functional properties or numbers of either CLEC-2-expressing
platelets or podoplanin-expressing MSCs.
Although mesenchymal cell migration has been extensively
investigated (reviewed by Eggenhofer et al., 2014), few studies
have analysed the molecular machinery regulating umbilical cord
mesenchymal stromal cell migration. We show for the first time
that RhoA–RhoC and ROCK act in opposing manners to regulate
podoplanin-independent cellular migration in umbilical cord
mesenchymal stem cells, with Rho providing pro-migratory signals
and ROCK inducing anti-migratory cues. By contrast, bothmolecules
have been reported to negatively regulate bone-marrowmesenchymal
stem cells; inhibiting Rho or ROCK promoted migration across
Fig. 5. Podoplanin-expressing MSCs can interact with platelets through endothelium. MSC and endothelial cell co-cultures (EC:MSC) were formed
on opposite sides of a porous insert. Endothelial cell (EC) mono-cultures were seeded as controls. (A) Untreated platelet-labelled whole blood was perfused
over the apical surface of filters for 10 min. In all cases, platelet adhesion and aggregation were assessed by using ImageJ particle analysis and expressed
as platelet coverage in µm2. *P<0.05 by paired t-test. (B) Platelet-labelled whole blood, untreated or treated with recombinant CLEC-2 (rCLEC-2), was perfused
over the apical surface of filters for 10 min. One-way ANOVA: P<0.05; *P<0.05 by Dunnett’s post-test compared to EC:MSC co-culture. Representative
fluorescent images of platelet interactions with (C) PDPN− or (D) PDPN+ MSCs in co-culture with ECs, or with PDPN+ MSC co-cultures in the (E) absence and
(F) presence of rCLEC-2. Data are mean±s.e.m. from (A) n=3 and (B) n=4 independent experiments using different biological donors for each cell type in
each independent experiment; n≥5 fields of view were analysed per treatment group. Scale bars: 200 µm.
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transwell filters (Jaganathan et al., 2007) whereas blocking ROCK
enhanced migration across ECs (Lin et al., 2013). Conversely, ROCK
has also been shown to provide pro-migratory signals and positively
regulate bone-marrow mesenchymal stem cell motility in response to
CXCL12 (Park et al., 2017) and HIF-1α (Choi et al., 2016). Clinical
trials involving systemic delivery of mesenchymal stem cells
therapies are growing, with much of the therapy becoming trapped
in the lungs (Schrepfer et al., 2007). Thus, there is an urgent need
to improve our understanding of the migratory machinery of
mesenchymal stem cell to improve their migration efficiency both
in the context of MSC cell based therapies, but also as a strategy
to stimulate the movement of endogenous MSCs to sites of
tissue-damage and inflammation.
Podoplanin expression contributes to a pro-migratory phenotype
in MSCs found in the perivascular space, lymphoid tissues (Astarita
et al., 2015) and tumours (Suchanski et al., 2017; Martin-Villar
et al., 2010; Neri et al., 2015; Wicki et al., 2006; Petrie et al., 2012).
Perivascular MSCs signal through Rac-1, which acts to maintain
podoplanin at the cell periphery and couple it to the cytoskeletal and
migration machinery. Combined, these enable perivascular MSCs
to protrude through the endothelial layer of the vessel wall,
presenting podoplanin in the vessel lumen, which captures and
activates circulating platelets in a CLEC-2-dependent manner.
Physiologically this may function to maintain vascular integrity by
localising MSCs to the perivascular space. However, this can also
have detrimental effects in, for example, cancer by contributing to
metastasis. Further work is required to dissect the physiological and
pathological roles of podoplanin, with a focus on the signalling
pathways linked to each scenario, to ascertain whether these differ in
a context-dependent manner that could potentially yield therapeutic
targets for, for example, metastasis.
MATERIALS AND METHODS
Isolation, culture and characterisation of MSCs
Umbilical cords were collected from anonymous donors with the assistance
of the Birmingham Women’s Health Care NHS Trust and Sandwell and
West Birmingham Hospitals NHS Trust. Mesenchymal stromal cells
(MSCs) were isolated from umbilical cords as previously described
(Munir et al., 2016), cultured in low-glucose Dulbecco’s modified Eagle’s
medium (DMEM) with stable levels of L-glutamine (Biosera, ZI du
Bousquet, France) supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 µg/ml streptomycin (all from Sigma-Aldrich)
and used at passage 3. MSCs were dissociated with EDTA/trypsin (Sigma)
as previously described (Munir et al., 2015), counted using a Cellometer
(Nexcelom Bioscience Ltd, Manchester, UK) and suspended at the final
desired concentration in culture medium.
Flow cytometry for podoplanin
Expression of podoplanin was analysed using 1.25 µg/ml phycoerythrin
(PE)-conjugated anti-podoplanin (clone NZ-1.3; batch 4284066;
eBioscience, now Thermo-Fisher, Paisley, UK) as previously reported
Fig. 6. Podoplanin-expressing MSCs can protrude through
endothelium.Cells cultured on Transwell filters (A–F) or in umbilical
cord tissue sections (G–L) were stained for podoplanin, along with
markers of ECs (CD31) and MSCs (CD90). (A) Monolayer of CD31-
positive ECs in green on the apical surface of the filter for an
EC:MSC co-culture filter. Arrows indicate red podoplanin staining on
the apical surface of the filter. (B) Monolayer of MSCs expressing
CD90 (in blue) and podoplanin (in red), where dual-positive cells are
purple, on the basal surface of the filter for an EC:MSC co-culture
filter. (C) Image obtained mid-way through the filter for an EC:MSC
co-culture. Arrows indicate podoplanin from the basal MSC layer
protruding up through the filter. Monolayer of CD31-positive ECs in
green on the (D) apical and (E) basal surface of the filter for an EC
mono-culture. (F) Image obtained mid-way through the filter for an
EC mono-culture. (G) CD90 expression in red around vessels in the
umbilical cord. (H) Podoplanin expression in blue around vessels in
the umbilical cord. (I) CD31 expression in green around vessels in
the umbilical cord. (J) CD31, podoplanin and CD90 expression
around vessels in the umbilical cord. The white box represents the
area magnified in panel K. (K) Zoomed image of CD31, podoplanin
and CD90 expression. White arrows indicate cells positive for CD31
and CD90, but not podoplanin. Yellow arrows indicate cells
appearing positive for all three markers. (L) CD31, podoplanin and
CD90 expression across the entire umbilical cord section. The white
box represents the zoomed in areas for G–J. Representative
confocal images, obtained of using Zen Black software, are shown.
Scale bars: 20 µm (A–F,K), 50 µm (G–J), 1 mm (L).
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(Sheriff et al., 2018). Control samples were incubated with isotype-matched
nonspecific conjugated antibodies. The level of expression was evaluated
using a Cyan ADP flow cytometer and data were analysed offline using
Summit 4.3 (both Beckman Coulter SA). Single positive MSCs were
classified into cell donors that were either positive (MFI>10) or negative
(MFI<10) for podoplanin (Sheriff et al., 2018).
siRNA knockdown of podoplanin
Podoplanin-positive or -negative MSCs (4.2×103 cells/mm2) were
transfected with Lipofectamine 2000 (Thermo-Fisher) containing either
two siRNA duplexes against podoplanin (50 nM; SASI_Hs01_00094891,
SASI_Hs01_00192618) or a single scrambled siRNA duplex control
(SIC001; all Sigma) for 6 h. Cells were washed with fresh medium and
cultured for up to 72 h. Podoplanin expression was assessed by quantitative
(q)PCR using Applied Biosystems Assay on Demand Primers (Thermo-
Fisher), with technical replicates (n=3) averaged for each sample, as
previously described (Munir et al., 2016) or by flow cytometry.
Migration assay
MSCs (2.4×103 cells/mm2) were seeded on the apical surface of 8 µm pore
12-well Transwell inserts (BD Falcon, SLS, Nottingham, UK) and allowed
to migrate for 48 h. The culture medium was removed from both chambers.
Cells were detached from the upper (apical) and lower (basal) surfaces of the
filter using trypsin (2.5 mg/ml, Sigma) and counted using a Z2-series
Coulter Counter (Beckman Coulter) as previously described (Jeffery et al.,
2013). Migration was quantified by counting the number of cells in the
lower chamber and expressing it as a percentage of the total number of cells
counted in both chambers. In some experiments, MSCs were treated with
siRNA for podoplanin or inhibitors against RhoA, RhoB and RhoC (CT04;
1, 2 or 4 µg/ml; Cytoskeleton), ROCK (Y27632; 10 or 100 µM; Sigma); or
Rac-1 (NSC23766; 1 or 10 µM; Calbiochem) for the duration of the
experiment. In cross-linking studies, MSCs were treated with anti-human
podoplanin antibody (5 µg/ml; clone NZ-1.3; batch 4308851) for 30 min,
followed by goat anti-rat IgG2a [30 µg/ml; PA1-84755; eBioscience now
ThermoFisher, UK (Langan et al., 2018)] for 48 h.
Collagen migration assay
Rat-tail collagen type 1 (2.15 mg/ml; First Link Ltd,WestMidlands, UK)was
mixed with 10× M199 (Gibco, Thermo-Fisher), and then neutralised by
addition of 1 N NaOH on ice, as described (Jeffery et al., 2013; Munir et al.,
2017). The gel was allowed to set for 15 min at 37°C, and then equilibrated
for 24 h with culture medium. MSC spheroids were formed by suspending
2.5×104 cells in 35 µl culture medium as a hanging droplet for 48 h, before
settling onto the surface of the collagen gel. MSCmigration over the collagen
gel was assessed at 24 h and 48 h using an Olympus X71 Fluorescent
Invert microscope enclosed at 37°C. Images were analysed off-line using
AngioSys2.0 software (Cellworks, Buckingham, UK) to quantify the number
of marginal cells (those cells disseminating from the edge of the spheroid on
the surface of the collagen gel). Data were expressed as the number of
marginal cells migrating away from the spheroid and along the surface of the
collagen matrix as a percentage of the total number of cells seeded.
Isolation and culture of ECs
Cryopreserved human dermal blood endothelial cells (BECs) were purchased
at passage 2 and cultured in Endothelial Cell Growth Media MV containing
Endothelial Cell Growth Media MV Supplement Mix as per the
manufacturer’s guidelines (PromoCell, Heidelberg, Germany). BECs were
dissociated with EDTA/trypsin as described above and used at passage 5.
Platelet isolation and pre-treatment
Venous blood was collected in tubes containing citrate-phosphate-
dextrose solution with adenine at a 10:1 ratio (Sigma). Platelets were
labelled by incubating whole blood with PE-conjugated mouse anti-
human CD41a antibody (1.88 µg/ml; clone 5B12; batch 20025383; Dako,
Cheshire, UK) for 10 min prior to use. In some experiments, 9 µM
integrilin (Sigma), an inhibitor of αIIbβ3-integrin (Thomas et al., 2011;
Sheriff et al., 2018), was added to CD41a-labelled whole blood
immediately prior to use.
Assessing MSC–platelet interactions – static adhesion assays
MSCs (2.4×103 cells/mm2) were cultured onto the basal surface (lower
chamber) of 0.4 or 3 µm pore 6-well Transwell inserts for 24 h as described
previously (Munir et al., 2016, 2017; McGettrick et al., 2017). The culture
medium was removed from both chambers. Phosphate-buffered saline with
Ca2+ and Mg2+ (PBS; Sigma) was added to the lower chamber. CD41a-
labelled whole blood was added to the apical surface (upper chamber) of the
filter for 1 h, before non-adherent cells were removed by washing. Adherent
platelets were imaged using an Olympus X71 Fluorescent Invert microscope
enclosed at 37°C. Adhesion and platelet aggregation were quantified by
using the Particle Analysis of Fluorescence function in ImageJ (NIH) and
expressed as platelet coverage in µm2.
Assessing MSC–platelet interactions – flow-based adhesion
assays
MSCs (2.4×103 cells/mm2) were cultured onto the basal surface of 3 µm
pore 6-well Transwell inserts as above. For some experiments, BECs
(1.0×104 cells/mm2) were seeded onto the apical surface of the filter and
co-cultured withMSCs for 24 h, as described previously (Munir et al., 2016,
2017; McGettrick et al., 2017). Filters were analysed by phase-contrast
microscopy prior to experimentation to confirm confluent monolayers of
MSCs or ECs, or both (Fig. S2A–D). Membrane integrity and permeability
was assessed through two independent measures: diffusion of 70 kDa FITC-
labelled dextran (2 mg/ml; Sigma) across a blank or cell-coated filters
(EC mono-cultures or EC–MSC co-cultures) over 1.5 h, where fluorescence
was determined by spectrometry (Fig. S2E). Transendothelial electrical
resistance (TER) across mono and co-culture filters was determined by
using a Millicell ERS (Millipore) and Endohm-6 (World Precision
Instruments, FL), with triplicate readings obtained for each filter, and data
are expressed as mean TER in ohms for cell-coated filters once the electrical
resistance of the culture medium was subtracted (Fig. S2F).
Subsequently, filters were incorporated into a parallel-plate flow
chamber, such that MSCs were on the ablumenal surface and BECs were
exposed to flow when included (Munir et al., 2016, 2017; McGettrick et al.,
2017). For some experiments, MSCs were pre-treated with 30 µg/ml of
human recombinant CLEC-2 protein (R&D systems) for 10 min prior to
perfusion (Suzuki-Inoue et al., 2007).
CD41a-labelled whole blood (untreated or treated with integrillin) was
perfused over the apical surface of the filter (i.e. the uncoated filter in MSC
mono-cultures or the BEC layer in the co-culture construct) for 5 min at a
wall shear rate of 150 s−1 (Navarro-Núñez et al., 2015). Digitised
fluorescent recordings of five random fields were made along the centre
line of the flow channel following 5 min of washout with PBS without Ca2+
and Mg2+ (Sigma) containing 5 U/ml heparin (Sagent Pharmaceuticals,
Schaumburg, IL). Images were analysed off-line using the ImageJ Particle
Analysis of Fluorescence function and data are expressed as platelet
coverage in µm2.
Confocal microscopy
MSCs (1.6×102 cells/mm2) seeded in microchannels (µ-Slide VI0.4; Ibidi,
Munich, Germany) were incubated with or without 10 µM NSC23766
for 24 h. Cells were fixed with formalin (10% neutral-buffered; Sigma) for
30 min, permeabilised with 0.5% Triton X-100 (Sigma) diluted in PBS for
10 min and blocked for 1 h with 1% bovine serum albumin and 10% goat
serum (both from Vector Laboratories) or 10% normal horse serum (NHS).
Cells were incubated with anti-human podoplanin antibody [5 µg/ml; clone
NZ-1.3; batch 4308851 (Mizoguchi et al., 2018)], followed by goat Alexa
Fluor 647-conjugated anti-rat-IgG antibody [10 µg/ml; A21247; batch
1834715; Invitrogen, Paisley, UK (Freeman et al., 2017)] or donkey Alexa
Fluor 647-conjugated anti-rat-IgG antibody [1:500; 712-606-153; batch
129952; Jackson ImmunoResearch (Mizoguchi et al., 2018)] for 1 h each.
Samples were counterstained with Alexa Fluor 488-conjugated phalloidin
(16.5 nM) for 30 min and mounted in ProLong Gold Antifade Mountant
containing DAPI (both from Thermo-Fisher) or ProLong Diamond Antifade
Mountant (Life Technologies). Samples were imaged using Zen software on
an LSM780 confocal microscope (both Zeiss) and analysed using ImageJ
software. Cell area was determined as the total area of phalloidin (F-actin)
staining divided by the number of nuclei per field of view, averaged and
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expressed as µm2. Podoplanin fluorescence intensity was determined using
the Integrated Density Function in ImageJ, which analysed the fluorescence
intensity in the Alexa Fluor 647 (podoplanin) channel and divided this by
the number of nuclei per field of view. Data are expressed as integrated
density/cell. Finally, the cellular location of podoplanin was assessed by
counting the number of cells expressing podoplanin (i) located at the tips of
pseudopod and (ii) diffuse within the membrane and intracellularly. These
data were expressed as a percentage of the total number of cells analysed in
all fields. Images in Fig. 3C were acquired using obtained using Zen Black
software on a Zeiss LSM880 confocal microscope in Airyscan mode (both
Zeiss) and analysed using FIJI (Schindelin et al., 2012).
To assess the cellular location of podoplanin, ECs were cultured alone
or co-cultured withMSCs on filters for 24 h prior to the filter being washed
in PBS, cut out of their holders and air dried. Membranes were fixed in
acetone for 20 min at 4°C prior to staining with rat anti-human podoplanin
[1:100; clone NZ-1.3; batch 4338663; Life Technologies (Mizoguchi
et al., 2018)], mouse anti-human CD31 [1:100; IgG2a; clone HEC7; batch
RA224581; Life Technologies (Link et al., 2011)] and mouse anti-human
CD90 [1:200; IgG1; clone F15-42-1; batch 2794897; Merck Millipore
(McKenzie and Fabre, 1981)] antibodies for 1 h, followed by staining with
secondary antibodies Alexa Fluor 546-conjugated goat anti-rat-IgG [1:500;
A11081; batch 1661229 (Quadrato et al., 2017)], Alexa Fluor 488-conjugated
goat anti-mouse IgG2a [1:200; A21131; batch 1744724 (Cesnekova et al.,
2016)] and Alexa Fluor 647-conjugated goat-anti-mouse IgG1 [1:500;
A21240; batch 1608639; all from Life Technologies (Rao et al., 2017)] and
Hoechst 33258. Filters were mounted between slides and coverslips using
Prolong DiamondAntifadeMountant. Samples were imaged on the Zeiss 880
LSM confocal microscope using linear imaging and de-convoluted with
appropriate colour controls using Zen Black software.
Alternatively 6 µm frozen umbilical cords sections were fixed in acetone
for 20 min at 4°C. Sections were rehydrated prior in PBS, and blocked in
10% NHS in PBS prior to staining with rat anti-human podoplanin [1:100;
clone NZ-1.3; batch 4338663; Life Technologies (Mizoguchi et al., 2018)],
mouse anti-human CD31 [1:100; IgG2a; clone HEC7; batch RA224581;
Life Technologies (Link et al., 2011)] and sheep anti-human CD90 [1:200;
AF2067; batch CGJL0117011; R&D Systems (Mizoguchi et al., 2018)]
antibodies for 1 h, followed by staining with secondary antibodies
Alexa Fluor 546-conjugated donkey anti-sheep-IgG [1:500; A21098;
batch 1776048; Life Technologies (Li et al., 2017)], Alexa Fluor 488-
conjugated donkey-anti-mouse-IgG [1:200; 715-546-151; batch 130065
(Dias et al., 2018)] and Alexa Fluor 647-conjugated donkey anti-rat-IgG
[1:500; 712-606-153; batch 129952; both from Jackson Immuno Research
(Mizoguchi et al., 2018)] and Hoechst 33258. Slides were imaged on the
Zeiss 880 LSM confocal microscope and the Zeiss AxioScan Z.1 and
analysed using Zen Black software and FIJI.
Ethics
The study was conducted in compliance with the Declaration of Helsinki.
All human samples were obtained with written, informed consent and
approval from the Human Biomaterial Resource Centre (Birmingham, UK),
North East – Tyne and West South Research Ethics Committee, or
University of Birmingham Local Ethical Review Committee.
Statistical analysis
Data are expressed as mean±s.e.m. or mean±s.d. as stated, where at least
three different MSC donors were incorporated in each independent
experiment. In all cases, treatment groups were randomised prior to assay.
Data were normally distributed, as assessed by Shapiro–Wilk normality test
in GraphPad Prism. Multi-variant data were analysed using analysis of
variance (ANOVA), followed by Bonferroni or Dunnett post-hoc tests.
Univariate datawere analysed using paired or unpaired t-tests as appropriate.
P≤0.05 was considered statistically significant.
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Suárez-Fueyo, A., Can ̃ete, J. D. and Pablos, J. L. (2014). Clinicopathological
correlations of podoplanin (gp38) expression in rheumatoid synovium and its
potential contribution to fibroblast platelet crosstalk. PLoS ONE 9, e99607.
Dias, D. O., Kim, H., Holl, D., Werne Solnestam, B., Lundeberg, J., Carlén, M.,
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